Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2025; 16(12): 112423
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.112423
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.112423
Liraglutide alleviates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by enhancing mitophagy mediated by the AMPK-Parkin signaling pathway
Ya-Xin Zhu, Wei Zhang, Hui-Lin Qu, Yue Zhang, Ruo-Qian Zhou, Ping Li, Fang Wang, Yan Zhang, Hui-Hui Liu, Sha Li, Qian Dong, Ke-Fei Dou, Yuan-Lin Guo, Jian-Jun Li, Rui-Xia Xu, Cardiometabolic Medicine Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
Co-first authors: Ya-Xin Zhu and Wei Zhang.
Co-corresponding authors: Jian-Jun Li and Rui-Xia Xu.
Author contributions: Zhu YX and Zhang W contribute equally to this study as co-first authors; Li JJ and Xu RX contribute equally to this study as co-corresponding authors; Zhu YX, Zhang W, Qu HL and Zhang Y contributed equally to the performance of the experiments, drafting the manuscript, analyzing the data and producing the figures; Zhou RQ and Zhang Y performed the literature research and statistical analysis; Liu HH, Li S and Dong Q contributed new reagents and analytic tools; Li P, Wang F and Dou KF provided clinical insights and supervised the writing of the written text; Guo YL, Li JJ and Xu RX conceptualized and designed the study; all authors have read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81370221 and No. 82172334; PUMC Youth Fund, No. 3332018200; National Science and Technology Major Project of the Ministry of Science and Technology of China, No. 2024ZD0522005; and CAMS Innovation Fund for Medical Science, No. 2016-CXGC05-4 and No. 2021-I2M-1-008.
Institutional animal care and use committee statement: The animal feeding and animal experiments of this project strictly follow the experimental animal welfare policy. All experimental operations and experimental inspections are carried out after the use of isoflurane. The researchers do their best to reduce and eliminate the fear and pain of experimental animals. The Sino Animal (Beijing) Science and Technology Development Co., Ltd approved the animal experimental research project (No. 20240234YZH-3R).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui-Xia Xu, PhD, Cardiometabolic Medicine Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 Beilishi Road, Xicheng District, Beijing 100037, China. ruixiaxu@sina.com
Received: August 11, 2025
Revised: September 28, 2025
Accepted: November 12, 2025
Published online: December 15, 2025
Processing time: 128 Days and 17.1 Hours
Revised: September 28, 2025
Accepted: November 12, 2025
Published online: December 15, 2025
Processing time: 128 Days and 17.1 Hours
Core Tip
Core Tip: This study investigates the cardioprotective effects of liraglutide, a glucagon-like peptide-1 receptor agonist, in a rat model of diabetic cardiomyopathy (DCM) and in neonatal rat cardiomyocytes exposed to high glucose and palmitate. Liraglutide sig